GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)

Wegovy and Zepbound are not the finish line — they are the current state of a fast-moving pipeline. A wave of next-generation incretin drugs is working through phase 2 and phase 3 trials, several reporting weight-loss magnitudes that rival or exceed today's injectables, plus new formats: oral pills, once-monthly shots, and triple-hormone mechanisms. This page is a living tracker — a single at-a-glance table of what is in development, how far along each compound is, and the peak weight loss reported so far — with every row linking to our full, individually-cited deep-dive. It is an index, not a substitute for those guides: cross-trial comparisons are unreliable (different populations, doses, durations, and analysis methods), phase 2 signals routinely shrink in phase 3, and none of the investigational agents below is FDA-approved for US weight loss.

The GLP-1 pipeline at a glance

Every figure above is the peak reported in that compound's program, not a like-for-like comparison — do not rank the drugs by these numbers alone. Read the linked guide for each one before drawing conclusions.

Approved and closest to approval

Orforglipron (Foundayo) is the milestone: the FDA approved it in April 2026 as the first once-daily oral small-molecule GLP-1 for chronic weight management, taken any time with no food or water rules. Its ~11% average weight loss trails the top injectables but its convenience is the story — see our ATTAIN obesity deep-dive and approval guide. Right behind it, CagriSema (Novo Nordisk) has an NDA filed after REDEFINE-1 showed 22.7% weight loss — impressive in absolute terms but below Novo's own ~25% target (REDEFINE breakdown). Eli Lilly's retatrutide, the triple agonist, posted up to 24.2% in phase 2 and is now reading out the phase 3 TRIUMPH program^[1] (retatrutide evidence). Amgen's once-monthly MariTide and Boehringer/Zealand's survodutide are both in phase 3 with phase 2 signals around 19-20%^[2] (pipeline challengers deep-dive).

Earlier-stage and non-US compounds

Amycretin (Novo Nordisk) is a unimolecular amylin/GLP-1 dual agonist in oral and injectable forms; the published human data is still phase 1 (roughly 13% at 12 weeks), so it is early but closely watched^[3] (amycretin guide). Mazdutide (Innovent) is a GLP-1/glucagon dual that is approved in China as of 2025 but is not legally marketed or FDA-approved in the US — GLORY-1 showed about 14% at the 6 mg dose^[4] (mazdutide evidence). Ecnoglutide (Sciwind, licensed to Pfizer for China) is a cAMP-biased GLP-1 running phase 3 trials in China.

Discontinued

Not every pipeline drug makes it. Pfizer discontinued danuglipron — it dropped the twice-daily form in 2023 and killed the once-daily program in April 2025. Tellingly, efficacy was never the problem (about 13% placebo-adjusted in phase 2b^[5]); the issues were tolerability and a liver-enzyme safety signal (why Pfizer pulled it). It is a useful reminder that a strong phase 2 weight number does not guarantee a finish.

How to read pipeline weight-loss numbers

• Do not compare across trials. These figures come from different populations, doses, durations, and statistical estimands. A 22% in one phase 3 and a 24% in another phase 2 are not directly rankable.
• Phase 2 signals usually shrink. Larger, longer, more diverse phase 3 populations — and the more conservative intention-to-treat estimands used for regulators — routinely bring the headline number down from the phase 2 peak.
• Approved abroad is not approved here. Mazdutide (China) and any ex-US compound cannot be legally prescribed or sold in the US until the FDA approves it. Buying "pipeline" drugs from grey-market sources is a real safety and legality risk.
• Investigational means not yet proven safe or effective for you. Only orforglipron on this list is FDA-approved for weight management. For what you can actually get prescribed today, see our semaglutide and tirzepatide provider rankings.